K. Ahn
11 Papers
K. Ahn is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 8 publications.
Chat about Author
Papers
Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial
Marcus Maurer,Sarbjit S. Saini,Kristi Mclendon,Paul A. Wabnitz,Sung-Han Kim,K. Ahn,Suyoung Kim,Sewon Lee,Clive Grattan +8 more
TL;DR: In this article , CT-P39 was evaluated as a biosimilar of reference omalizumab and demonstrated pharmacokinetic equivalence with EU-, EU-, and US-omalizumabs following a single dose in healthy individuals.
5
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
Claire F. Verschraegen,Z. Andric,Fedor Moiseenko,T. C. Makharadze,Sergii Shevnya,A. Oleksiienko,Eduardo Yanez Ruiz,Sung-Han Kim,K. Ahn,Taehong Park,Sijin Park,Hana Ju,Yuichiro Ohe +12 more
TL;DR: In this paper , CT-P16 and EU-bevacizumab were compared in patients with metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC).
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial
Justin Stebbing,Yauheni Valerievich Baranau,V. Baryash,Vladimir Moiseyenko,Dmytro Boliukh,N. Antone,Alexey Manikhas,A. Chornobai,Taehong Park,Eric Hyungseok Baek,Jaeyong Lee,Jiin Choi,Nahyun Kim,K. Ahn,Sang Joon Lee,Sung-Han Kim +15 more
TL;DR: The CT-P6 3.2 study as discussed by the authors demonstrated equivalent efficacy and comparable safety between CTP6 and reference trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer after up to 3 years' follow-up.
Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea
Seok-Goo Cho,Jae-Cheol Jo,Young-Woo Jeon,Dajung Kim,Deok-Hwan Yang,Won Sik Lee,Yoon Seok Choi,Jun Ho Yi,Dok Hyun Yoon,Jee Hyun Kong,Jung-Yoon Choe,Sung-Hyun Kim,K. Ahn,Taehong Park,Jeongah Park,Sang-Gyeom Han +15 more
TL;DR: In this paper , a Korean post-marketing surveillance (PMS) study evaluated the safety and effectiveness of CT-P10 in the firstly approved indications in Korea: non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangitis (MPA).
1
Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.
Ajanee Mahakkanukrauh,Sumapa Chaiamnuay,A. Koolvisoot,Tassanee Kitamnuayphong,Siriporn Manavathongchai,Manathip Osiri,Worawit Louthrenoo,Parichat Uea-Areewongsa,K. Ahn,N. Jung,Minkyung Kim,Seulgi Lee,Hanna Kim,Sung-Han Kim +13 more
TL;DR: This open-label, multicenter study evaluated the safety and effectiveness of CT-P13 in Thai patients with inflammatory arthritis, finding it well-tolerated and effective in improving disease activity across RA, AS, and PsA indications over 46 weeks.
1